Industry News

MannKind Corporation, a developer of devices for treatment of diabetes. Before his death, Mann staged offerings for the company on both Nasdaq and the Tel Aviv Stock Exchange."/>
Alfred Mann's legacy stimulates Israeli innovation [Globes, Tel Aviv, Israel]
GlaxoSmithKline Pharmaceuticals Ltd shares have lost a fifth of their value. The company's financial performance has been hit by supply constraints in FY16 and some of that has continued into FY17 as well. Price controls have hurt too."/>
GSK Pharma: in the recovery room [Mint, New Delhi]
Mylan NV and Biocon Ltd on Thursday said the European Medicines Agency has agreed to review Mylan's application seeking permission to bring Trastuzumab to Europe. Trastuzumab is a proposed biosimilar--copycat version of a biotech drug--that they developed together to treat certain types of breast and gastric cancers. A biosimilar is a complex biological product that follows a different approval pathway compared to chemical drugs."/>
European regulator EMA to review Biocon-Mylan cancer drug [Mint, New Delhi]
Insys Therapeutics deceptively marketed and sold Subsys-- a spray form of the prescription opioid drug fentanyl-- to physicians treating patients for conditions such as neck and back pain. "This drug company's desire for increased..."/>
Illinois sues drugmaker, alleges it pushed opioid spray for non-FDA use [Chicago Tribune]
Medtronic PLC in its fiscal first quarter despite a dip in sales. The company reported unadjusted net income of $929 million, or 66 cents per share, compared with $820 million, or 57 cents a share for the same period a year ago. Its adjusted net income of $1.03 per share beat Wall Street estimates by 2 cents."/>
Medtronic beats estimates despite a decline in sales [Star Tribune (Minneapolis)]
Medtronic Spine, a division of Dublin-based medical device maker Medtronic Plc, today reported a 5.8 percent decline in global revenue for the first quarter. For the quarter that ended July 29, the division reported revenue of $645 million, compared with $685 million a year ago. The company reported that new products and procedural innovation are factors that should lead to improved results."/>
Memphis-based Medtronic Spine revenue down 6 percent [The Commercial Appeal, Memphis, Tenn.]
Transition Therapeutics Inc. is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders. A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders in person or by proxy. The Arrangement was..."/>
Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.
Transition Therapeutics Inc. is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders. A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders in person or by proxy."/>
Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.
Mettler-Toledo International Inc. will replace Johnson Controls Inc. in the S&P 500, S&P SmallCap 600 constituent Monolithic Power Systems, Inc. will replace Mettler-Toledo in the S&P MidCap 400, and WCI Communities Inc. will replace Monolithic Power Systems in the S&P SmallCap 600 after the close of..."/>
Mettler-Toledo International Set to Join the S&P 500; Monolithic Power Systems to Join S&P MidCap 400; WCI Communities and Nautilus to Join S&P SmallCap 600
INC Research Holdings, Inc., a leading global Phase I to Phase IV contract research organization, today announced that it will participate in two upcoming investor conferences. Presenting at the conferences will be Greg Rush, Chief Financial Officer.. Rush is scheduled to present during the upcoming 2016 Wells Fargo Healthcare Conference on Wednesday, Sept. 7, 2016 at 1:45 p.m. Eastern Time."/>
INC Research to Present at Upcoming September Conferences
LeMaitre Vascular, Inc. announced today that JJ Pellegrino, Chief Financial Officer, will present at the 9 th Annual Barrington Research Fall Investment Conference on Thursday, September 8, 2016 at the Four Seasons Hotel in Chicago, IL.. For more information or to register, please visit the conference website at www.brai.com. LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that..."/>
LeMaitre Vascular to Attend the 9th Annual Barrington Research Fall Investment Conference on September 8, 2016
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the fourth quarter and fiscal year ended June 30, 2016.. Fiscal 2016 versus Fiscal 2015. Net sales of $558.5 million versus $547.0 million, a 2.1% increase Gross profit of $142.8 million versus $135.4 million, a 5.4%..."/>
ACETO Reports Fiscal 2016 Fourth Quarter and Record Full Year Results
Cigna has become the first national insurer to cover three-dimensional mammograms for routine breast cancer screening. Medicare and Connecticut's Medicaid program already cover the technology for routine mammograms, which are free to women 40 and older with insurance since Obamacare's passage. But Cigna, Aetna, UnitedHealthcare and Anthem were hesitant, as there is not yet clear data to show that 3- D mammograms save more lives than traditional mammograms."/>
Cigna Becomes First National Insurer To Cover 3-D Mammograms [The Hartford Courant]
PharmAthene, Inc., a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority the Company has withdrawn the protest filed on August 5, 2016.. PharmAthene is a biodefense company engaged in the development of next generation medical countermeasures against biological threats. The Company's development portfolio..."/>
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
Sunshine Heart, Inc., today announced that on August 18, 2016, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved four equity awards, to be effective as of August 22, 2016, under Sunshine Heart’ s New-Hire Equity Incentive Plan, as material inducements to four individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing..."/>
Sunshine Heart Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AMSURG Corp. today announced that its Board of Directors has declared a quarterly dividend of $1.3125 per share in cash for the Company’ s 5.250% Mandatory Convertible Preferred Stock, Series A-1. The dividend is payable on October 1, 2016, to shareholders of record as of September 15, 2016.. AMSURG’ s Ambulatory Services Division acquires, develops and operates ambulatory surgery centers in partnership with physicians throughout the U.S."/>
AMSURG Declares Quarterly Preferred Stock Dividend
Humana Inc. announced today that its Board of Directors has declared a cash dividend to stockholders of $0.29 per share payable on October 28, 2016 to stockholders of record as of the close of business on October 13, 2016.. As contemplated by the Company’ s merger agreement with Aetna Inc., Humana has aligned the record and payment dates of this quarterly dividend with those of Aetna’ s next expected quarterly dividend. Humana Inc., headquartered in Louisville, Ky.,..."/>
Humana Board Declares Payment of Quarterly Dividend to Stockholders
Walgreens Boots Alliance, Inc. today announced that it had agreed with AmerisourceBergen Corporation to amend the second tranche of warrants held by Walgreens Boots Alliance to purchase AmerisourceBergen common stock, so as to permit the immediate exercise of these warrants. The warrants were originally scheduled to be exercisable in March 2017.. Walgreens Boots Alliance then exercised these warrants and purchased 22,696,912 shares of..."/>
Walgreens Boots Alliance Exercises Second Tranche of Warrants to Purchase AmerisourceBergen Shares
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management is scheduled to present at the following upcoming investor conferences:. Event: Wells Fargo 2016 Healthcare Conference Location: Boston, MA at the Westin Boston Waterfront Hotel Date: Thursday, September 8, 2016 Time: 9:20 a.m. ET/ 6:20 a.m. PT."/>
Nevro to Present at Upcoming Investor Conferences

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary667 Articles
Information Technology618 Articles
Financials524 Articles
Health Care372 Articles
Industrials372 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.